Background: Effective blood pressure (BP)-lowering therapy is regarded as the most
important intervention in diabetes mellitus. Nebivolol is commonly used for the treatment of …

Background: In patients with diabetes mellitus type 2 and arterial hypertension, the control of
systolic and diastolic blood pressure is essential to reduce the risk of adverse events. The …

Background and Objectives: Hypertension is a widely prevalent con-dition of elevated blood
pressure (BP) and is the leading risk factor for the development of cardiovascular disease …

Background: The antihypertensive activity of beta-blockers generally increases during the
first 6 to 8 weeks of treatment; however, no study has systematically assessed whether blood …

Background Nebivolol represents a therapeutic class of beta blockers with high beta 1
selectivity and modulatory effect on vascular reactions by releasing nitric oxide (NO) from …

This double‐blind, multicenter, randomized placebo‐controlled study evaluated the
antihypertensive efficacy and safety of nebivolol, a selective β1‐adrenoreceptor blocker with …

Nebivolol has been adequately tested in clinical efficacy trials of patients with mild
hypertension. Clinical efficacy trials or their metaanalyses did not accurately predict the …

In this multicenter trial, the effects of nebivolol added to an angiotensin‐converting enzyme
(ACE) inhibitor or angiotensin II receptor blocker (ARB) were assessed in patients with …

This study assessed blood pressure (BP) reductions and response rates following addition
of nebivolol to ongoing antihypertensive therapy in patients with uncontrolled stage I–II …

Background and objective Lowering BP to normal levels without quality of life deterioration
is the most important means of reducing cardiovascular risk. Recent studies have …